
Opinion|Videos|January 2, 2025
Overview of Port Delivery System With Ranibizumab
Panelists discuss how the port delivery system (PDS) is a permanent, refillable ocular implant that continuously releases ranibizumab into the vitreous, with the Archway trial demonstrating noninferior vision outcomes compared with monthly ranibizumab injections while reducing treatment burden through 6-month refill intervals.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Can you provide an overview of the PDS with ranibizumab approved for treating neovascular age-related macular degeneration?
- How does the device function?
- Could you discuss the key outcomes from the Archway trial for PDS?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
The Retina TL;DR with Dr. Weng: Navigating the ocular risks of facial fillers with Jennifer Murdock, MD
2
Retina World Congress 2026: Can vibration reduce pain during intravitreal injections?
3
Retina World Congress 2026: Sunir J. Garg, MD, FACS, on preventing occupational injury in retina practice
4
Retina World Congress 2026: Diagnosing macular telangiectasia in a field of mimickers
5






















